Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG

M Tomana, K Matousovic, BA Julian, J Radl… - Kidney international, 1997 - Elsevier
M Tomana, K Matousovic, BA Julian, J Radl, K Konecny, J Mestecky
Kidney international, 1997Elsevier
Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with
IgG. IgA1 proteins from sera of patients with IgA nephropathy (IgAN) are galactosylated to a
lesser degree than those from healthy controls. The increased reactivity of intact or de-
sialylated serum IgA1 with N-acetylgalactosamine (GalNAc)-specific lectins, Helix aspersa
(HAA) and Caragana arborescens (CAA) and de-sialylated IgA1 with Helix pomatia (HPA)
and Bauhinia purpurea (BPA) indicated that the Gal deficiency is in glycans located in the …
Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. IgA1 proteins from sera of patients with IgA nephropathy (IgAN) are galactosylated to a lesser degree than those from healthy controls. The increased reactivity of intact or de-sialylated serum IgA1 with N-acetylgalactosamine (GalNAc)-specific lectins, Helix aspersa (HAA) and Caragana arborescens (CAA) and de-sialylated IgA1 with Helix pomatia (HPA) and Bauhinia purpurea (BPA) indicated that the Gal deficiency is in glycans located in the hinge region of IgA1 molecules. De-sialylated IgA from sera of 81 IgAN patients bound biotin-labeled lectin HAA more effectively than did de-sialylated IgA from 56 healthy controls (P < 0.0001). Similar results were observed for 67 IgAN patients and 52 controls with second lectin, CAA (P < 0.001). The binding patterns for 9 patients with mesangial proliferative glomerulonephritis of non-IgA origin were similar to those for controls. Incompletely galactosylated IgA1 capable of binding GalNAc-specific lectins was detected in complexes with IgG as demonstrated by ELISA, size-exclusion chromatography and sucrose gradient ultracentrifugation. The formation of IgA1-IgG complexes may affect the serum level of IgA1 by reducing the rate of its elimination and catabolic degradation by the liver.
Elsevier